Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02PYN
|
||||
| Former ID |
DNCL002607
|
||||
| Drug Name |
SR 16234
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Phase 2 | [531682] | ||
| Company |
SRI International
|
||||
| Formula |
C39H55NO10
|
||||
| Canonical SMILES |
CCN(CC)CC1=CC(=C(C=C1)OCCC2CCC3C2(CCC4C3C(CC5=C4C=CC(=C<br />5)O)C)C)OC.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
|
||||
| InChI |
1S/C33H47NO3.C6H8O7/c1-6-34(7-2)21-23-8-13-30(31(19-23)36-5)37-17-15-25-9-12-29-32-22(3)18-24-20-26(35)10-11-27(24)28(32)14-16-33(25,29)4;7-3(8)1-6(13,5(11)12)2-4(9)10/h8,10-11,13,19-20,22,25,28-29,32,35H,6-7,9,12,14-18,21H2,1-5H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t22-,25-,28-,29+,32-,33-;/m1./s1
|
||||
| InChIKey |
VOHOCSJONOJOSD-SCIDSJFVSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Modulator | [550429] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||